Already a member? Sign in
Zolpidem tartrate is a sedative-hypnotic drug that is used for short-term treatment of insomnia that presents as difficulty of sleep onset and maintenance of sleep.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Insomnia | 990 | 318 |
|
|
|
|
|
| Sleep problems | 318 | 106 |
|
|
|
|
|
| Difficulty sleeping through night | 216 | 54 |
|
|
|
|
|
| Other | 138 | 25 |
|
|
|
|
|
| Fibromyalgia | 122 | 41 |
|
|
|
|
|
| Difficulty falling asleep | 62 | 17 |
|
|
|
|
|
See all 1732 patients currently taking Zolpidem
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Zolpidem
| Amnesia | 46 | |
|---|---|---|
| Grogginess | 36 | |
| Groggy in morning | 35 | |
| Drowsy in a.m. | 28 | |
| Sleep-related eating with amnesia | 22 | |
| Sleep Walking | 20 | |
| See all 104 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Zolpidem. See all 57 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 172 | ||
| Side effects too severe | 128 | ||
| Doctor's advice | 117 | ||
| Other | 116 | ||
| Course of treatment ended | 41 | ||
| Expense | 39 | ||
| Personal research | 20 | ||
| Change in health plan coverage | 18 | ||
| Not indicated | 14 |
Adherence
Taking treatment as prescribed
Adherence of Zolpidem
Always |
376 | 66% |
|
|---|---|---|---|
Usually |
106 | 19% |
|
Sometimes |
67 | 12% |
|
Never |
19 | 3% |
|
Burden
Difficulty being on treatment
Burden of Zolpidem
Very |
24 | 4% |
|
|---|---|---|---|
Somewhat |
42 | 7% |
|
A little |
72 | 13% |
|
Not at all |
430 | 76% |
|
Cost
Paid out of pocket
Cost of Zolpidem
$200+ |
2 | 0% |
|
|---|---|---|---|
$100-199 |
3 | 1% |
|
$50-99 |
23 | 6% |
|
$25-49 |
60 | 15% |
|
< $25 |
321 | 78% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 11, 2012.